VivoSeq
Other

Borderline Resectable

0

Pipeline Programs↗

4

Active Trials↗

0

Companies Involved↗

Borderline Resectable is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

13/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Unknown status3 · 38%
Recruiting3 · 38%
Not yet recruiting1 · 13%
Withdrawn1 · 13%

Clinical Trials

Trial Activity

8 trials

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Recruiting·PProton Collaborative Group·Phase 2·NCT02598349·60 enrolled
Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC
Recruiting·—·Phase 1·NCT05085496·12 enrolled
Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
Recruiting·LLei ZHAO·Phase 2·NCT06904014·40 enrolled
Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
Not yet recruiting·—·Phase 2·NCT06998719·80 enrolled
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
Withdrawn·National Cancer Institute (NCI)·Phase 2·NCT04044950
Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer
Unknown status·UUniversity of Virginia·Phase 2·NCT01333332·35 enrolled
The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases
Unknown status·NNational Cheng-Kung University Hospital·Phase 2·NCT03711240·40 enrolled
The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC
Unknown status·SSichuan University·Phase 1/2·NCT05042336·49 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)